Organ-Chip Quantitative Analysis: How To Confidently Predict Toxicity Of Preclinical Drug Candidates With The Emulate Liver-Chip
Drug-induced liver injury (DILI) is a potentially fatal condition that significantly impacts the pharmaceutical industry, leading to drug withdrawals and about 13% of clinical trial failures. The high incidence of DILI highlights the limitations of preclinical toxicology models in replicating the complexity of human liver physiology and drug responses.
Recent studies indicate that incorporating the Emulate Liver-Chip into preclinical workflows could decrease DILI-related clinical trial failures. We introduce a quantitative framework for integrating Liver-Chip data into pharmaceutical decision-making. This new Liver-Chip DILI score allows researchers to categorize compounds into standard DILI risk categories using human Liver-Chip and animal in vivo data.
Specifically, this webinar covers:
- Characterization results of the Emulate Liver-Chip for DILI prediction
- Integration points for the Liver-Chip in the preclinical workflow
- Using the Liver-Chip’s quantitative readouts to classify therapeutics into DILI risk categories
- Methodology for combining Liver-Chip data with animal in vivo data for a comprehensive DILI risk assessment
The presentation concluded with an informative Q&A session.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.